AI Generated
Oct 19, 2026, 10:33
Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
Pallavi Madhiraju, Website Owner at CricketHerald.com, shared a post on LinkedIn:
“European regulators have reaffirmed their negative recommendation for YARTEMLEA, even though the FDA approved the same medicine for transplant associated thrombotic microangiopathy in December 2025.
Omeros Corporation disputes the review process, while the EMA says its concerns about clinical evidence remain unresolved.
The company now plans to end its European compassionate use programme.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke